PA007531.r1: Recombinant Anti-mouse VEGFR-2 Monoclonal Antibody (Clone: DC101), Rat IgG1 Kappa
Recombinant Rat IgG1 Monoclonal Antibody.
Clone: DC101.
Isotype: Rat IgG1 Kappa.
Source: The anti-mouse VEGFR-2 monoclonal antibody (clone: DC101) was produced in mammalian cells.
Conjugation: non-conjugated.
Specificity/Sensitivity: The recombinant VEGFR-2 monoclonal antibody (clone: DC101) specifically binds to the mouse VEGFR-2.
Applications: Flow cytometry (FC), and Immunohistochemistry - Frozen (IHC-F).
Form of Antibody: 0.2 uM filtered solution, pH 7.4, containing 0.09% sodium azide.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.
PA007531.h1Fs: Recombinant Anti-mouse VEGFR-2 Monoclonal Antibody (Clone: DC101), Human IgG1 Fc Silent Kappa
Recombinant Human IgG1 Monoclonal Antibody.
Clone: DC101.
Isotype: Human IgG1 Fc Silent Kappa.
Source: The anti-mouse VEGFR-2 monoclonal antibody (clone: DC101) was produced in mammalian cells.
Conjugation: non-conjugated.
Specificity/Sensitivity: The recombinant VEGFR-2 monoclonal antibody (clone: DC101) specifically binds to the mouse VEGFR-2.
Applications: Flow cytometry (FC), and Immunohistochemistry - Frozen (IHC-F).
Form of Antibody: 0.2 uM filtered solution, pH 7.4, containing 0.09% sodium azide.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.
Shipping: The recombinant anti-mouse VEGFR-2 antibodies (clone of DC101) are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, 2 to 8°C as supplied. Do not freeze it.
Syd Labs provides the following anti-mouse PD1 (PD-L1) and VEGFR2 monoclonal antibodies:
In vivo grade recombinant anti-mouse PD-1 monoclonal antibodies (Clone RMP1-14.1)
In vivo grade recombinant anti-mouse PD 1 monoclonal antibodies (Clone 29F.1A12.1)
In vivo grade recombinant anti-mouse PD-L1 monoclonal antibodies (Clone 10F.9G2.1)
In vivo grade recombinant anti-mouse VEGFR2 monoclonal antibodies (Clone DC101)
Syd Labs provides the following anti-mouse PD-1 / VEGFR-2 bispecific antibodies:
In vivo grade recombinant anti-mouse PD 1 / VEGFR2 bispecific antibodies (Clone RMP1-14.1 / DC101)
In vivo grade recombinant anti-mouse PD-1 / VEGFR-2 bispecific antibodies (Clone 29F.1A12.1 / DC101)
Syd Labs provides the following anti-mouse PD-L1 / VEGFR-2 bispecific antibodies:
In vivo grade recombinant anti-mouse PDL1 / VEGFR-2 bispecific antibodies (Clone 10F.9G2.1 / DC101)
References of anti-mouse VEGFR-2 antibody for Flow Cytometry (Clone: DC101):
Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody
Park, J. A., et al. J Immunother Cancer. 2023 Apr;11(4):e006150. doi: 10.1136/jitc-2022-006150. PMID: 36990507
Anti-human VEGF (bevacizumab, BVZ) or anti-mouse VEGFR2 antibody (DC101) was used as VEGF blockade, and ex vivo armed T cells (EATs) carrying anti-GD2, anti-HER2, or anti-glypican3 (GPC3) IgG-(L)-scFv platformed BsAb were used. Mice-bearing HGSOC1 osteosarcoma PDX were treated with T cells armed ex vivo with anti-HER2-BsAb (HER2-EATs) with or without VEGF blockade using BVZ (anti-hVEGF) or DC101 (anti-mVEGFR2). Luciferase transduced T cells armed with anti-HER2-BsAb (Luc (+) HER2-EATs) were administered in combination with BVZ or with DC101 to mice bearing HGSOC1 osteosarcoma PDX. Neuroblastoma PDXs were treated with a combination of GD2-EATs and anti-VEGF (BVZ) or VEGFR2 antibody (DC101). Combinations of GD2-EATs and anti-VEGF (BVZ) (G4) or anti-VEGFR2 antibody (DC101) (G5) induced high endothelial venules (HEVs) in tumors.
Tags: activity of DC101 antibody; function of DC101 antibody
VEGFR2 blockade enhances CAR T-cell infiltration into brain tumors via normalization of tumor vessels
Huang, Y., et al. Cancer Immunol Res. 2022 Sep 2;10(9):1024-1036. doi: 10.1158/2326-6066.CIR-21-0965. PMID: 35794010
DC101, an anti-mouse VEGFR2 neutralizing antibody, was administered intraperitoneally at 40 mg/kg twice weekly to normalize tumor vasculature in orthotopic GBM mouse models. Flow cytometry analysis of dissociated tumors revealed a significant increase in CD8+ T cell infiltration (from 5% to 18%) in DC101-treated mice compared to controls. VEGFR2 expression on CD31+ endothelial cells was quantified by flow cytometry, showing 85% blockade efficiency post-DC101 treatment. Combined DC101 and CAR-T therapy extended median survival from 28 to 52 days in the GL261 model. Tumor single-cell suspensions were stained with anti-CD45, anti-CD3, and anti-CD8 antibodies for flow cytometric evaluation of immune cell populations.
Tags: DC101 antibody; DC101 antibody for animal model
Anti-VEGFR2 therapy promotes antitumor immunity in glioblastoma by enhancing dendritic cell migration
Woroniecka, K., et al. Clin Cancer Res. 2021 Dec 15;27(24):6771-6783. doi: 10.1158/1078-0432.CCR-21-1285. PMID: 34580351
Mice were treated with anti-mouse VEGFR-2 antibody (DC101, 10 mg/kg i.p.) starting 7 days post-tumor implantation to modulate the tumor microenvironment. Flow cytometry of brain-infiltrating leukocytes demonstrated a 3-fold increase in CD11c+ MHCII+ dendritic cells in DC101-treated tumors. DC101 blockade reduced VEGFR2+ pericyte coverage on vessels, as assessed by co-staining with anti-NG2 and anti-CD31 in flow cytometry. Therapeutic efficacy was validated by combining DC101 with anti-PD-1, resulting in 40% long-term survivors. Peripheral blood mononuclear cells were isolated and analyzed by flow cytometry for VEGFR2 expression on monocytes pre- and post-treatment.
Tags: DC101 antibody for flow cytometry; DC101 antibody for mouse tumor model
DC101 enhances immune checkpoint blockade in colorectal cancer models
Wallin, J. J., et al. Cancer Immunol Res. 2019 Jul;7(7):1113-1125. doi: 10.1158/2326-6066.CIR-18-0710. PMID: 31061123
Anti-mouse VEGFR-2 (DC101) was dosed at 100 mg/kg weekly in MC38 syngeneic tumors to synergize with anti-PD-1 therapy. Flow cytometry revealed upregulated CD8+ T cell activation markers (IFN-?, Granzyme B) in DC101 + checkpoint inhibitor-treated mice. Tumor endothelial cells (CD45- CD31+) showed diminished VEGFR2 surface expression by 70% after DC101 administration, confirmed via flow cytometry. Vascular normalization by DC101 improved nanoparticle delivery, quantified by flow cytometric detection of labeled particles in TILs. Multicolor flow panels included anti-VEGFR2, anti-CD31, and viability dyes to profile the vascular compartment.
Tags: DC101 mAb for animal model; DC101 mAb for flow cytometry
A VEGFR2?MICA bispecific antibody activates tumor-infiltrating lymphocytes and exhibits potent anti-tumor efficacy in mice
Xu, Y., et al. Cancer Immunol Immunother. 2019 Dec;68(12):1961-1973. doi: 10.1007/s00262-019-02379-9. PMID: 31428800
DC101, an anti-mouse VEGFR2 antibody, was purchased from BioXCell (West Lebanon, NH, USA). The positive control DC101 was stained with PE-conjugated goat anti-rat IgG antibody (Biolegend, USA). DC101 was a commercial anti-mouse VEGFR2 antibody. At the same dose level of 200 nM, the apoptosis rate of JZC00 (Fig. 3c) and JZC01 (Fig. 3d) was roughly similar. DC101 was set as the positive control (Fig. 3e), and PBS was set as the negative control (Fig. 3f). JZC01 and JZC00 possessed similar binding to those two cell lines, but little binding was seen with rMICA treatment (Fig. 2c, d) and DC101 was set as a positive control.
Tags: DC101 mAb; DC101 monoclonal antibody
For more references about anti-mouse VEGFR-2 antibody for Flow Cytometry (Clone: DC101), please contact our scientific support team with message@sydlabs.com.